

Madrid, June 29, 2026

Pursuant to the provisions of Article 228 of Law 6/2023, of March 17, on Securities Markets and Investment Services, and related provisions, as well as Circular 3/2020 on information to be provided by companies listed on the BME Growth segment of BME MTF Equity (the “**BME Growth Circular 3/2020**”), LABIANA HEALTH, S.A. (“LABIANA” or the “Company”) hereby provides the following:

OTHER RELEVANT INFORMATION

NOTICE OF CHANGE IN SIGNIFICANT SHAREHOLDINGS

LABIANA announces that SONNTAG Premium has acquired 675,000 common shares of the Company.

Following the completion of the aforementioned transaction, SONNTAG Premium’s direct stake now represents 7.95% of the Company’s share capital, constituting a significant stake within the entity’s shareholding structure.

As of June 29, 2026, the shareholders with a direct or indirect stake equal to or greater than 5% of LABIANA’s share capital are:

SHAREHOLDER	DIRECT OWNERSHIP	INDIRECT HOLDING	TOTAL STAKE
Manuel Ramos (1)		46.45%	46.45%
BLUECOLT, S.A.	35.01%		35.01%
ORTEGA FARMING, S.L.	11.43%		11.43%
John William Nellis	10.83%		10.83%
Ances Mei	5.80%		5.80%
SONNTAG Premium	7.95%		7.95%

(1) Indirect ownership through the companies BLUECOLT, S.A. and ORTEGA FARMING, S.L.

The Board of Directors is not aware of the existence, as of that date, of any other shareholders holding positions equal to or greater than 5% of the share capital.

In accordance with the provisions of BME Growth Circular 3/2020, it is hereby noted that the information disclosed has been prepared under the sole responsibility of the Company and its directors.

Mr. Manuel Ramos Ortega,
Chairman and Chief Executive
Officer of LABIANA HEALTH, S.A.